Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011, Article ID 138471, 10 pages
http://dx.doi.org/10.4061/2011/138471
Research Article

MPTP Neurotoxicity and Testosterone Induce Dendritic Remodeling of Striatal Medium Spiny Neurons in the C57Bl/6 Mouse

1Neuroscience Graduate Program, University of Southern California, Los Angeles, CA 90033, USA
2Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
3Department of Neurology, Keck School of Medicine, Department of Biokinesiology, University of Southern California, Los Angeles, CA 90033, USA

Received 11 September 2010; Accepted 27 March 2011

Academic Editor: Katerina Venderova

Copyright © 2011 Eleni Antzoulatos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. M. Garcia-Segura, J. A. Chowen, A. Parducz, and F. Naftolin, “Gonadal hormones as promoters of structural synaptic plasticity: cellular mechanisms,” Progress in Neurobiology, vol. 44, no. 3, pp. 279–307, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. L. M. Garcia-Segura, I. Azcoitia, and L. L. DonCarlos, “Neuroprotection by estradiol,” Progress in Neurobiology, vol. 63, no. 1, pp. 29–60, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Białek, P. Zaremba, K. K. Borowicz, and S. J. Czuczwar, “Neuroprotective role of testosterone in the nervous system,” Polish Journal of Pharmacology, vol. 56, no. 5, pp. 509–518, 2004. View at Google Scholar · View at Scopus
  4. L. M. Shulman and V. Bhat, “Gender disparities in Parkinson's disease,” Expert Review of Neurotherapeutics, vol. 6, no. 3, pp. 407–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Fahn, “Description of Parkinson's disease as a clinical syndrome,” Annals of the New York Academy of Sciences, vol. 991, pp. 1–14, 2003. View at Google Scholar · View at Scopus
  6. J. B. Becker, “Oestrogen effects on dopaminergic function in striatum,” Novartis Foundation Symposium, vol. 230, pp. 134–151, 2000. View at Google Scholar · View at Scopus
  7. D. E. Dluzen, “Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system,” Journal of Neurocytology, vol. 29, no. 5-6, pp. 387–399, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Schober, “Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP,” Cell and Tissue Research, vol. 318, no. 1, pp. 215–224, 2004. View at Publisher · View at Google Scholar
  9. D. E. Dluzen, J. L. McDermott, and B. Liu, “Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice,” Neurotoxicology and Teratology, vol. 18, no. 5, pp. 603–606, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. K. A. Disshon and D. E. Dluzen, “Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release,” Brain Research, vol. 764, no. 1-2, pp. 9–16, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Dluzen, “Estrogen decreases corpus striatal neurotoxicity in response to 6- hydroxydopamine,” Brain Research, vol. 767, no. 2, pp. 340–344, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. D. B. Miller, S. F. Ali, J. P. O'Callaghan, and S. C. Laws, “The impact of gender and estrogen on striatal dopaminergic neurotoxicity,” Annals of the New York Academy of Sciences, vol. 844, pp. 153–165, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. H. E. Murray, A. V. Pillai, S. R. Mcarthur et al., “Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females,” Neuroscience, vol. 116, no. 1, pp. 213–222, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. P. J. Shughrue, “Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERα and ERβ),” Experimental Neurology, vol. 190, no. 2, pp. 468–477, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. A. C. Ferraz, F. Matheussi, R. E. Szawka et al., “Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle,” Neurochemical Research, vol. 33, no. 7, pp. 1238–1246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. B. Becker, “Gender differences in dopaminergic function in striatum and nucleus accumbens,” Pharmacology Biochemistry and Behavior, vol. 64, no. 4, pp. 803–812, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bourque, D. E. Dluzen, and T. Di Paolo, “Neuroprotective actions of sex steroids in Parkinson's disease,” Frontiers in Neuroendocrinology, vol. 30, no. 2, pp. 142–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. D. E. Dluzen, “Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice,” Brain Research, vol. 715, no. 1-2, pp. 113–118, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Ekue, J. F. Boulanger, M. Morissette, and T. Di Paolo, “Lack of effect of testosterone and dihydrotestosterone compared to 17β-oestradiol in 1-methyl-4-phenyl-1,2,3,6,tetrahydropyridine-mice,” Journal of Neuroendocrinology, vol. 14, no. 9, pp. 731–736, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Dluzen, R. Jain, and B. Liu, “Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity,” Journal of Neurochemistry, vol. 62, no. 1, pp. 94–101, 1994. View at Google Scholar · View at Scopus
  21. G. E. Gillies, H. E. Murray, D. Dexter, and S. McArthur, “Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease,” Pharmacology Biochemistry and Behavior, vol. 78, no. 3, pp. 513–522, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Jackson-Lewis, M. Jakowec, R. E. Burke, and S. Przedborski, “Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Neurodegeneration, vol. 4, no. 3, pp. 257–269, 1995. View at Google Scholar · View at Scopus
  23. M. W. Jakowec, K. Nixon, E. Hogg, T. McNeill, and G. M. Petzinger, “Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway,” Journal of Neuroscience Research, vol. 76, no. 4, pp. 539–550, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Paxinos and K. Franklin, The Mouse Brain in Stereotaxic Coordinates, Academic Press, New York, NY, USA, 2001.
  25. B. E. Fisher, G. M. Petzinger, K. Nixon et al., “Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia,” Journal of Neuroscience Research, vol. 77, no. 3, pp. 378–390, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. G. M. Petzinger, J. P. Walsh, G. Akopian et al., “Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury,” Journal of Neuroscience, vol. 27, no. 20, pp. 5291–5300, 2007. View at Publisher · View at Google Scholar
  27. D. M. Gomez and S. W. Newman, “Medial nucleus of the amygdala in the adult syrian hamster: a quantitative golgi analysis of gonadal hormonal regulation of neuronal morphology,” Anatomical Record, vol. 231, no. 4, pp. 498–509, 1991. View at Google Scholar · View at Scopus
  28. R. Gibb and B. Kolb, “A method for vibratome sectioning of Golgi-Cox stained whole rat brain,” Journal of Neuroscience Methods, vol. 79, no. 1, pp. 1–4, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Kurosaki, Y. Muramatsu, H. Watanabe et al., “Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice,” Metabolic Brain Disease, vol. 18, no. 2, pp. 139–146, 2003. View at Publisher · View at Google Scholar
  30. M. M. Monaghan, L. Leddy, M. -L. A. Sung et al., “Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease,” Neurodegenerative Diseases, vol. 7, no. 1–3, pp. 153–159, 2010. View at Publisher · View at Google Scholar
  31. E. Petroske, G. E. Meredith, S. Callen, S. Totterdell, and Y. S. Lau, “Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment,” Neuroscience, vol. 106, no. 3, pp. 589–601, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. M. G. Vučković, R. I. Wood, D. P. Holschneider et al., “Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury,” Neurobiology of Disease, vol. 32, no. 2, pp. 319–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. S. McArthur, H. E. Murray, A. Dhankot, D. T. Dexter, and G. E. Gillies, “Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition,” Journal of Neurochemistry, vol. 100, no. 3, pp. 678–692, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Day, Z. Wang, J. Ding et al., “Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models,” Nature Neuroscience, vol. 9, no. 2, pp. 251–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Pulipparacharuvil, W. Renthal, C. F. Hale et al., “Cocaine regulates MEF2 to control synaptic and behavioral plasticity,” Neuron, vol. 59, no. 4, pp. 621–633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. C. A. Vickers, B. Stephens, J. Bowen, G. W. Arbuthnott, S. G. N. Grant, and C. A. Ingham, “Neurone specific regulation of dendritic spines in vivo by post synaptic density 95 protein (PSD-95),” Brain Research, vol. 1090, no. 1, pp. 89–98, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. K. E. Lyons, J. P. Hubble, A. I. Tröster, R. Pahwa, and W. C. Koller, “Gender differences in Parkinson's disease,” Clinical Neuropharmacology, vol. 21, no. 2, pp. 118–121, 1998. View at Google Scholar · View at Scopus
  38. C. A. Haaxma, B. R. Bloem, G. F. Borm et al., “Gender differences in Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 8, pp. 819–824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Antzoulatos, M. W. Jakowec, G. M. Petzinger, and R. I. Wood, “Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease,” Pharmacology Biochemistry and Behavior, vol. 95, no. 4, pp. 466–472, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. M. D. Neely, D. E. Schmidt, and A. Y. Deutch, “Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons,” Neuroscience, vol. 149, no. 2, pp. 457–464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. A. D. Smith and J. P. Bolam, “The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones,” Trends in Neurosciences, vol. 13, no. 7, pp. 259–265, 1990. View at Google Scholar · View at Scopus
  42. I. N. Krasnova and J. L. Cadet, “Methamphetamine toxicity and messengers of death,” Brain Research Reviews, vol. 60, no. 2, pp. 379–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Li, B. Kolb, and T. E. Robinson, “The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudate-putamen,” Neuropsychopharmacology, vol. 28, no. 6, pp. 1082–1085, 2003. View at Google Scholar · View at Scopus
  44. J. P. Jedynak, J. M. Uslaner, J. A. Esteban, and T. E. Robinson, “Methamphetamine-induced structural plasticity in the dorsal striatum,” European Journal of Neuroscience, vol. 25, no. 3, pp. 847–853, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. T. E. Robinson and B. Kolb, “Structural plasticity associated with exposure to drugs of abuse,” Neuropharmacology, vol. 47, no. 1, pp. 33–46, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. J. H. Baik, R. Picetti, A. Saiardi et al., “Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors,” Nature, vol. 377, no. 6548, pp. 424–428, 1995. View at Google Scholar · View at Scopus
  47. M. Xu, Y. Guo, C. V. Vorhees, and J. Zhang, “Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor,” Brain Research, vol. 852, no. 1, pp. 198–207, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Drago, C. R. Gerfen, J. E. Lachowicz et al., “Altered striatal function in a mutant mouse lacking D(1A) dopamine receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 26, pp. 12564–12568, 1994. View at Publisher · View at Google Scholar · View at Scopus
  49. D. M. Camp, J. B. Becker, and T. E. Robinson, “Sex differences in the effects of gonadectomy on amphetamine-induced rotational behavior in rats,” Behavioral and Neural Biology, vol. 46, no. 3, pp. 491–495, 1986. View at Google Scholar · View at Scopus
  50. X. Gao and D. E. Dluzen, “The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system,” Brain Research, vol. 892, no. 1, pp. 63–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. D. E. Dluzen, L. I. Anderson, and C. F. Pilati, “Methamphetamine-gonadal steroid hormonal interactions: effects upon acute toxicity and striatal dopamine concentrations,” Neurotoxicology and Teratology, vol. 24, no. 2, pp. 267–273, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. R. E. Myers, L. I. Anderson, and D. E. Dluzen, “Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice,” Neuropharmacology, vol. 44, no. 5, pp. 624–632, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Lewis and D. E. Dluzen, “Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice,” Neuroscience Letters, vol. 448, no. 1, pp. 130–133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Leranth, O. Petnehazy, and N. J. MacLusky, “Gonadal hormones affect spine synaptic density in the CA1 hippocampal subfield of male rats,” Journal of Neuroscience, vol. 23, no. 5, pp. 1588–1592, 2003. View at Google Scholar · View at Scopus
  55. J. A. Cherry, S. A. Tobet, T. J. DeVoogd, and M. J. Baum, “Effects of sex and androgen treatment on dendritic dimensions of neurons in the sexually dimorphic preoptic/anterior hypothalamic area of male and female ferrets,” Journal of Comparative Neurology, vol. 323, no. 4, pp. 577–585, 1992. View at Google Scholar · View at Scopus
  56. P. J. Shughrue, “Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERα and ERβ),” Experimental Neurology, vol. 190, no. 2, pp. 468–477, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. S. W. Mitra, E. Hoskin, J. Yudkovitz et al., “Immunolocalization of estrogen receptor β in the mouse brain: comparison with estrogen receptor α,” Endocrinology, vol. 144, no. 5, pp. 2055–2067, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. M. F. Kritzer, “Selective colocalization of immunoreactivity for intracellular gonadal hormone receptors and tyrosine hydroxylase in the ventral tegmental area, substantia nigra, and retrorubral fields in the rat,” Journal of Comparative Neurology, vol. 379, no. 2, pp. 247–260, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. E. J. Roy, D. R. Buyer, and V. A. Licari, “Estradiol in the striatum: effects on behavior and dopamine receptors but no evidence for membrane steroid receptors,” Brain Research Bulletin, vol. 25, no. 2, pp. 221–227, 1990. View at Publisher · View at Google Scholar · View at Scopus
  60. A. D. Ramirez, X. Liu, and F. S. Menniti, “Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice,” Neuroendocrinology, vol. 77, no. 4, pp. 223–231, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. D. E. Dluzen, J. L. McDermott, and B. Liu, “Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release,” Journal of Neurochemistry, vol. 66, no. 2, pp. 658–666, 1996. View at Google Scholar · View at Scopus
  62. M. Ookubo, H. Yokoyama, S. Takagi, H. Kato, and T. Araki, “Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice,” Molecular and Cellular Endocrinology, vol. 296, no. 1-2, pp. 87–93, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Küppers and C. Beyer, “Expression of aromatase in the embryonic and postnatal mouse striatum,” Molecular Brain Research, vol. 63, no. 1, pp. 184–188, 1998. View at Publisher · View at Google Scholar · View at Scopus
  64. C. E. Roselli and J. A. Resko, “Sex differences in androgen-regulated expression of cytochrome P450 aromatase in the rat brain,” Journal of Steroid Biochemistry and Molecular Biology, vol. 61, no. 3–6, pp. 365–374, 1997. View at Publisher · View at Google Scholar · View at Scopus
  65. C. K. Wagner and J. I. Morrell, “Distribution and steroid hormone regulation of aromatase mRNA expression in the forebrain of adult male and female rats: a cellular-level analysis using in situ hybridization,” Journal of Comparative Neurology, vol. 370, no. 1, pp. 71–84, 1996. View at Publisher · View at Google Scholar · View at Scopus
  66. C. K. Wagner and J. I. Morrell, “Neuroanatomical distribution of aromatase mRNA in the rat brain: indications of regional regulation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 61, no. 3–6, pp. 307–314, 1997. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Ragonese, M. D'Amelio, G. Salemi et al., “Risk of Parkinson disease in women: effect of reproductive characteristics,” Neurology, vol. 62, no. 11, pp. 2010–2014, 2004. View at Google Scholar · View at Scopus
  68. R. A. Popat, S. K. Van Den Eeden, C. M. Tanner et al., “Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease,” Neurology, vol. 65, no. 3, pp. 383–390, 2005. View at Publisher · View at Google Scholar · View at Scopus